Evolving Fibrinolytic Option in the Management of Second Stage of Empyema
Alawady, T., Elsharawy, M., Elfakharany, K., Samra, S., Abdelsalam, A. (2022). Evolving Fibrinolytic Option in the Management of Second Stage of Empyema. EKB Journal Management System, 28(5), 1141-1146. doi: 10.21608/zumj.2022.128169.2528
Tamer Alawady; Mamdouh Elsharawy; Karim Elfakharany; Saad Rabie Samra; Ashraf Hamed Abdelsalam. "Evolving Fibrinolytic Option in the Management of Second Stage of Empyema". EKB Journal Management System, 28, 5, 2022, 1141-1146. doi: 10.21608/zumj.2022.128169.2528
Alawady, T., Elsharawy, M., Elfakharany, K., Samra, S., Abdelsalam, A. (2022). 'Evolving Fibrinolytic Option in the Management of Second Stage of Empyema', EKB Journal Management System, 28(5), pp. 1141-1146. doi: 10.21608/zumj.2022.128169.2528
Alawady, T., Elsharawy, M., Elfakharany, K., Samra, S., Abdelsalam, A. Evolving Fibrinolytic Option in the Management of Second Stage of Empyema. EKB Journal Management System, 2022; 28(5): 1141-1146. doi: 10.21608/zumj.2022.128169.2528

Evolving Fibrinolytic Option in the Management of Second Stage of Empyema

Zagazig University Medical Journal
Article 31, Volume 28, Issue 5, September 2022, Page 1141-1146  XML PDF (373.98 K)
Document Type: Original Article
DOI: 10.21608/zumj.2022.128169.2528
View on SCiNiTO View on SCiNiTO
Authors
Tamer Alawady email 1; Mamdouh Elsharawy2; Karim Elfakharany3; Saad Rabie Samra4; Ashraf Hamed Abdelsalam5
1Cardiothoracic Surgery Department, Faculty Medicine, Zagazig University, Zagazig, Egypt
2Cardiothoracic Surgery, Faculty of Medicine, Zagazig University, Egypt
3Cardiothoracic Surgery Department, Faculty of Medicine, Zagazig University, Egypt
4Chest Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
5Cardiothoracic Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Abstract
Abstract
Objective: Intrapleural fibrinolytics installation is considered an alternative method to aggressive operative intervention. This conservative medical management may decrease morbidity and mortality that were recorded with surgery. Our study investigates the outcome of tissue plasminogen activator (TPA), alteplase, and streptokinase (SK) as a treatment for stage II of empyema. Methods: This study prospectively evaluated 38 patients that had stage II of empyema. The patients were divided into two groups with installing one fibrinolytic protocol into chest tube for each group; group A, (TPA) and group B, (SK). The evaluation was based upon clinical examination and radiological findings for efficacy of each protocol. Results: There were no differences in baseline characteristics between both groups. There was a significant improvement after 1st, where 11 patients (52.4%) improved in TPA group with only 3 patients (17.6%) in SK group. TPA group showed 100% success on the other hand SK Group had 2 patients failure (11.8%) and surgical intervention was necessary for them. Hemorrhagic complications were 9.5% and 17.6% for TPA and SK respectively. Finally, there was a significant prolonged duration of mean hospital stay with SK therapy (5.48 vs 8.59 days). Conclusion: Both fibrinolytic protocols were effective and safe for empyema management, but Alteplase had better outcome.
Keywords
Empyema; Fibrinolytic therapy; Intra-pleural installation; Tissue plasminogen activator; Streptokinase
Statistics
Article View: 197
PDF Download: 148